First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations

The prognostics implications of patients with acute myeloid leukemia harboring non-canonical FLT3 is unknown. The use of tyrosine kinase inhibitors in this patient population has not been previously reported. We report successful targeted therapy against non-ITD, non-D835 driver FLT3 alterations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Daver, Naval, Price, Allyson, Benton, Christopher B., Patel, Keyur, Zhang, Weiguo, Konopleva, Marina, Pemmaraju, Naveen, Takahashi, Koichi, Andreeff, Michael, Borthakur, Gautam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479234/
https://www.ncbi.nlm.nih.gov/pubmed/32984009
http://dx.doi.org/10.3389/fonc.2020.01538
Descripción
Sumario:The prognostics implications of patients with acute myeloid leukemia harboring non-canonical FLT3 is unknown. The use of tyrosine kinase inhibitors in this patient population has not been previously reported. We report successful targeted therapy against non-ITD, non-D835 driver FLT3 alterations in two patient case studies with acute myeloid leukemia.

Ejemplares similares